Photo of Yuangen Chen

Yuangen Chen

Print ProfilePrint Profile


  • MD, Jiangxi Medical College

  • Dongxiang Hospital
    Department of Medicine

  • New York Medical College
    Microbiology and Immunology

  • M.D., Jiangxi Medical College

  • Ph.D., Shanghai Medical College, Fudan University

  • Fellowship, Oncology
    New York Medical College


    Yuangen Chen, M.D, Ph.D, joined the Department of Neurosurgery in January 2005, coming from New York Medical College, Valhalla, New York, where he was a Research Associate in the Department of Microbiology and Immunology. Preceding that, he held appointments first as Assistant Professor and then Associate professor in the Division of Gastroenterology at Shanghai Medical College, Fudan University in Shanghai, China. In the Department, Dr. Chen will be supervising intraoperative monitoring of brain, spinal cord, and peripheral nervous system during neurosurgical procedures using somatosensory evoked potentials (SSEPs), brainstem auditory evoked potentials (BAEPs), motor evoked potentials (MEPs), stimulated EMG, peripheral nerve action potentials and electroencephalogram (EEG).


  • 1996 -
    Excellent Physician
    Huashan Hospital

  • 1995 -
    Top Prize, The third national award of Omeprazole Research
    Chinese Digestive Association


The effects of anesthetics on SSEPs and MEPs intraoperatively.


Tadi K, Ashok BT, Chen Y, Banerjee D, Wysocka-Skrzela B, Konopa J, Darzynkiewicz A, Tiwari PK. Preclinical evaluation of 1-nitroacridine derived chemotherapeutic agent that has preferential cytotoxic activity towards prostate cancer. Cancer Biol Ther 2007 Oct; 6(10): 1632-1637.

Ashok BT, Tadi K, Garikapaty VS, Chen Y, Huang Q, Banerjee D, Konopa J, Tiwari RK. Preclinical toxicological examination of a putative prostate cancer-specific 4-methyl-1-nitroacridine derivative in rodents. Anticancer 2007; 18(1): 87-94.

Tadi K, Chang Y, Ashok BT, Chen Y, Moscatello A, Schaefer SD, Schantz SP, Policastro AJ, Geliebter J, Tiwari RK. 3.3'-Diindolylmethane, a cruciferous vegetable derived synthetic anti-proferative compound in thyroid disease. Biochem Biophys Res Commun 2005 Nov 25; 337(3): 1019-1025.

Suriano R, Ghosh SK, Ashok BT, Mittelman A, Chen YG, Chen Y, Banerjee A, Tiwari RK. Differences in glycosylation patterns of heat shock protein, gp96: Implications for prostate cancer prevention. Cancer Res 2005 Jul 15; 65(14): 6466-6475.

Garikapaty VP, Ashok BT, Chen YG, Mittelman A, Iatropoulos M, Tiwari RK. Anti-carcinogenic and anti-metastatic properties of indole-3-carbinol in prostate cancer. Oncol Rep 2005 Jan; 13(1): 89-93.

Chen YG, Ashok BT, Liu X, Garikapaty VP, Mittelman A, Tiwari RK. Induction of heat shock protein gp96 by immune cytokines. Cell Stress Chaperones 2003; 8(3): 242-248.

Ashok BT, David L, Chen YG, Garikapaty VP, Chander B, Kanduc D, Mittelman A, Tiwari RK. Peptide mimotopes of oncoproteins as therapeutic agents in breast cancer. Int J Mol Med 2003; 11(4): 465-471.

Ashok BT, Chen YG, Liu X, Garikapaty VP, Seplowitz R, Tschorn J, Roy K, Mittelman A, Tiwari RK. Multiple molecular targets of indole-3-carbinol, a chemopreventive anti-estrogen in breast cancer. Eur J Cancer Prev 2002 Aug; 11(Suppl 2:S): 86-93.

Ashok BT, Chen YG, Liu X, Bradlow HL, Mittelman A, Tiwari RK. Abrogation of estrogen-mediated cellular and biochemical effects by indole-3-carbinol. Nutr Cancer 2001; 41(1-2): 180-187.

Wang L, Lu W, Chen YG, Zhou XM, Gu JR. Comparison of gene expression between normal colon mucosa and colon carcinoma by means of messenger RNA differential display. World J Gastroenterol 1999 Dec; 5(6): 533-534.

Industry Relationships

Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.

Dr. Chen did not report having any of the following types of financial relationships with industry during 2013 and/or 2014: consulting, scientific advisory board, industry-sponsored lectures, service on Board of Directors, participation on industry-sponsored committees, equity ownership valued at greater than 5% of a publicly traded company or any value in a privately held company. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.

Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website at Patients may wish to ask their physician about the activities they perform for companies.

Edit profile in Sinai Central


Annenberg Building Floor 8 Room 42
1468 Madison Avenue
New York, NY 10029

Tel: 212-241-0744


Annenberg Building Floor 8 Room 42
1468 Madison Avenue
New York, NY 10029

Tel: 212-241-0744